MX2022008659A - Moléculas de anticuerpos específicos contra c5ar1 y usos de estas. - Google Patents

Moléculas de anticuerpos específicos contra c5ar1 y usos de estas.

Info

Publication number
MX2022008659A
MX2022008659A MX2022008659A MX2022008659A MX2022008659A MX 2022008659 A MX2022008659 A MX 2022008659A MX 2022008659 A MX2022008659 A MX 2022008659A MX 2022008659 A MX2022008659 A MX 2022008659A MX 2022008659 A MX2022008659 A MX 2022008659A
Authority
MX
Mexico
Prior art keywords
antibody molecules
c5ar1
c5arl
anca
vasculitis
Prior art date
Application number
MX2022008659A
Other languages
English (en)
Spanish (es)
Inventor
Zachary Shriver
Karthik Viswanathan
Boopathy Ramakrishnan
Brian Booth
Andrew Wollacott
Gregory Babcok
Original Assignee
Visterra Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Visterra Inc filed Critical Visterra Inc
Publication of MX2022008659A publication Critical patent/MX2022008659A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2022008659A 2020-01-13 2021-01-13 Moléculas de anticuerpos específicos contra c5ar1 y usos de estas. MX2022008659A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062960544P 2020-01-13 2020-01-13
PCT/US2021/013284 WO2021146320A1 (en) 2020-01-13 2021-01-13 Antibody molecules to c5ar1 and uses thereof

Publications (1)

Publication Number Publication Date
MX2022008659A true MX2022008659A (es) 2022-11-10

Family

ID=74554227

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022008659A MX2022008659A (es) 2020-01-13 2021-01-13 Moléculas de anticuerpos específicos contra c5ar1 y usos de estas.

Country Status (13)

Country Link
US (3) US11773179B2 (https=)
EP (1) EP4090680A1 (https=)
JP (1) JP2023510844A (https=)
KR (1) KR20220160542A (https=)
CN (1) CN115443290A (https=)
AU (1) AU2021207627A1 (https=)
BR (1) BR112022013780A2 (https=)
CA (1) CA3166505A1 (https=)
IL (1) IL294661A (https=)
MX (1) MX2022008659A (https=)
TW (1) TWI869528B (https=)
WO (1) WO2021146320A1 (https=)
ZA (1) ZA202208280B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
AU2022207985A1 (en) * 2021-01-13 2023-07-06 Visterra, Inc. Humanized complement 5a receptor 1 antibodies and methods of use thereof
CN118829654A (zh) * 2021-12-29 2024-10-22 舒泰神(加州)生物科技有限公司 特异性识别C5aR1的抗体及其应用
CN114315990B (zh) * 2022-03-10 2022-05-27 北京康乐卫士生物技术股份有限公司 新型冠状病毒特异性单克隆抗体的制备及其应用
CN121816363A (zh) * 2023-06-27 2026-04-07 舒泰神（北京）生物制药股份有限公司 包含特异性识别C5aR1和GM-CSFRα的抗原结合域的多特异性抗体
CN119431573B (zh) * 2024-12-03 2025-08-22 江苏华创誉通医学检验有限公司 一种atg16l1单克隆抗体及其用途

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
JPS63501765A (ja) 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング　インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
ATE352612T1 (de) 1990-08-29 2007-02-15 Pharming Intellectual Pty Bv Homologe rekombination in säugetier-zellen
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
EP0575485A1 (en) 1991-03-01 1993-12-29 Dyax Corp. Process for the development of binding mini-proteins
DK0580737T3 (da) 1991-04-10 2004-11-01 Scripps Research Inst Heterodimere receptorbiblioteker ved anvendelse af phagemider
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
AU701578B2 (en) 1992-08-21 1999-02-04 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US5480974A (en) 1993-06-18 1996-01-02 The Scripps Research Institute Antibodies to human C5a receptor
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
EP2371861B1 (en) 2002-01-25 2017-08-09 Novo Nordisk A/S Monoclonal antibodies against extracellular loops of C5aR
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20060235208A1 (en) 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
WO2004029207A2 (en) 2002-09-27 2004-04-08 Xencor Inc. Optimized fc variants and methods for their generation
AU2003290605A1 (en) 2002-11-05 2004-06-03 The Regents Of The University Of Michigan Compositions and methods for the diagnosis and treatment of sepsis
JP2006524039A (ja) 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
ES2314383T3 (es) 2003-03-17 2009-03-16 Bayer Healthcare Ag Diagnostico y tratamiento terapeuticos para enfermedades asociadas al receptor 5a del componente del complemento (c5ar).
CN1871259A (zh) 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 具有改变的效应物功能的经改进的抗体和制备它的方法
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
US8399618B2 (en) 2004-10-21 2013-03-19 Xencor, Inc. Immunoglobulin insertions, deletions, and substitutions
WO2005050199A1 (en) 2003-10-31 2005-06-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein- coupled receptor 77 (gpr77)
WO2005060739A1 (en) 2003-12-24 2005-07-07 G2 Inflammation Pty Ltd Transgenic non-human mammal comprising a polynucleotide encoding human or humanized c5ar
CA2552788C (en) 2004-01-12 2013-09-24 Applied Molecular Evolution, Inc. Fc region variants
CN103172731A (zh) 2004-07-15 2013-06-26 赞科股份有限公司 优化的Fc变体
EP1810035A4 (en) 2004-11-10 2010-03-17 Macrogenics Inc GENERATION OF FC ANTIBODY REGIONS FOR EFFECTOR FUNCTION
US20100166741A1 (en) 2006-07-13 2010-07-01 Genentech , Inc. Altered br-3 binding polypeptides
EP2061812A4 (en) 2006-08-22 2010-06-09 G2 Inflammation Pty Ltd METHOD FOR THE PRODUCTION OF ANTIBODIES
MX2009001914A (es) * 2006-08-22 2009-03-31 G2 Inflammation Pty Ltd Anticuerpos anti-c5ar con propiedades mejoradas.
WO2008092117A2 (en) 2007-01-25 2008-07-31 Xencor, Inc. Immunoglobulins with modifications in the fcr binding region
WO2009005651A2 (en) 2007-06-29 2009-01-08 The Trustees Of The University Of Pennsylvania Complement-mediated thrombophilic assay
EP2229410A4 (en) 2007-12-05 2012-07-04 Massachusetts Inst Technology AGLYCOSYLATED IMMUNOGLOBULIN MUTANES
EP2254911B1 (en) * 2008-02-20 2015-11-25 Novo Nordisk A/S Humanized anti-c5ar antibodies
WO2009108931A2 (en) 2008-02-28 2009-09-03 Case Western Reserve University Method of treating cancer
US20180256646A1 (en) 2008-03-06 2018-09-13 Case Western Reserve University Compositions and methods for modulating toll like receptor signal
NZ597259A (en) 2009-06-23 2014-04-30 Alexion Pharma Inc Bispecific antibodies that bind to complement proteins
WO2011044368A1 (en) 2009-10-07 2011-04-14 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
EP2327725A1 (en) 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
ES2751549T3 (es) 2009-11-30 2020-04-01 Janssen Biotech Inc Mutantes de anticuerpos Fc con funciones efectoras ablacionadas
US10053513B2 (en) 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
WO2011100477A2 (en) * 2010-02-10 2011-08-18 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
TWI667346B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
RS67768B1 (sr) 2010-11-30 2026-03-31 Chugai Pharmaceutical Co Ltd Terapijski agens koji indukuje citotoksičnost
TWI812066B (zh) 2010-11-30 2023-08-11 日商中外製藥股份有限公司 具有鈣依存性的抗原結合能力之抗體
US11130801B2 (en) 2011-01-13 2021-09-28 Case Western Reserve University Method for inhibiting platelet derived growth factor signaling with C3aR or C5aR antibodies
AU2012214643B2 (en) 2011-02-07 2016-12-15 Research Development Foundation Engineered immunoglobulin Fc polypeptides
AR085302A1 (es) 2011-02-24 2013-09-18 Sanofi Sa Metodo de produccion de anticuerpos sialilados
CN112812184A (zh) 2011-02-25 2021-05-18 中外制药株式会社 FcγRIIb特异性Fc抗体
SG10201602394QA (en) 2011-03-29 2016-05-30 Roche Glycart Ag Antibody FC Variants
EP2698431B1 (en) 2011-03-30 2020-09-09 Chugai Seiyaku Kabushiki Kaisha Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity
AU2012250924B2 (en) 2011-05-02 2017-05-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
PL2718322T3 (pl) 2011-06-06 2019-07-31 Novo Nordisk A/S Lecznicze przeciwciała
CN109517059B (zh) 2011-06-30 2023-03-28 中外制药株式会社 异源二聚化多肽
EP2729496B8 (en) 2011-07-06 2017-10-18 Genmab A/S Modulation of complement-dependent cytotoxicity through modifications of the c-terminus of antibody heavy chains
LT2794658T (lt) 2011-12-19 2017-05-10 Synimmune Gmbh Bispecifinė antikūno molekulė
JP6226752B2 (ja) 2012-02-09 2017-11-08 中外製薬株式会社 抗体のＦｃ領域改変体
WO2013165690A1 (en) 2012-04-30 2013-11-07 Medimmune, Llc Molecules with reduced effector function and extended half-lives, compositions, and uses thereof
EP4310191A3 (en) 2012-06-14 2024-05-15 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing modified fc region
BR112015000167B1 (pt) 2012-07-06 2021-11-23 Genmab B.V. Proteína dimérica, proteína, composição, kit de partes e seus usos, bem como método para aumentar a oligomerização em solução de uma proteína dimérica compreendendo um primeiro e segundo polipeptídeo, cada um compreendendo pelo menos as regiões ch2 e ch3 de uma cadeia pesada de igg1 humana e proteína dimérica variante
WO2014012085A2 (en) 2012-07-13 2014-01-16 Zymeworks Inc. Bispecific asymmetric heterodimers comprising anti-cd3 constructs
TW202237660A (zh) 2012-08-24 2022-10-01 日商中外製藥股份有限公司 FcγRIIb特異性Fc區域變異體
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
RU2687043C2 (ru) 2013-04-29 2019-05-06 Ф. Хоффманн-Ля Рош Аг МОДИФИЦИРОВАННЫЕ АСИММЕТРИЧНЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕ Fc-РЕЦЕПТОР, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
CN105392803B (zh) 2013-05-08 2019-12-06 诺和诺德股份有限公司 C5aR拮抗剂的用途
WO2014190441A1 (en) 2013-05-31 2014-12-04 Zymeworks Inc. Heteromultimers with reduced or silenced effector function
AU2014306002B2 (en) 2013-08-07 2017-05-25 Alexion Pharmaceuticals, Inc. Atypical hemolytic uremic syndrome (aHUS) biomarker proteins
JP6668345B2 (ja) 2014-11-21 2020-03-18 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 修飾された重鎖定常領域を含む抗体
KR101860280B1 (ko) 2014-12-19 2018-05-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
US10526408B2 (en) 2015-08-28 2020-01-07 Research Development Foundation Engineered antibody FC variants
CA2997745A1 (en) 2015-09-14 2017-03-23 Children's Hospital Medical Center Methods and compositions for treatment of gaucher disease via modulation of c5a receptor
CN106957366B (zh) 2016-01-12 2022-02-01 上海昀怡健康科技发展有限公司 一种C5aR抗体及其制备方法和应用
SG11201900616UA (en) 2016-08-02 2019-02-27 Visterra Inc Engineered polypeptides and uses thereof
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
JP7471819B2 (ja) 2016-10-06 2024-04-22 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 工程不純物への結合が低下している抗体
FR3058159B1 (fr) 2016-10-28 2022-02-25 Lab Francais Du Fractionnement Variants de polypeptide fc presentant une demi-vie augmentee
JP7231549B2 (ja) 2017-02-06 2023-03-01 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法
WO2018183520A1 (en) 2017-03-28 2018-10-04 Lyvgen Biopharma Holdings Limited Therapeutic agents and methods for enhancing immune responses in tumor microenvironment
TWI826364B (zh) 2017-04-03 2023-12-21 德商因夫萊亞斯有限公司 活性抑制劑於發炎性疾病之治療
US11492415B2 (en) 2017-04-07 2022-11-08 Kookmin University Industry Academy Antibody Fc variants for increased blood half-life
IL270596B2 (en) 2017-05-25 2026-01-01 Bristol Myers Squibb Co Antibodies containing heavy constant regions are adapted for use in cancer therapy
KR20200012907A (ko) 2017-05-25 2020-02-05 브리스톨-마이어스 스큅 컴퍼니 변형된 IgG1 Fc 도메인 및 그와의 항-CD40 도메인 항체 융합체
CN111328335A (zh) 2017-06-07 2020-06-23 根马布私人有限公司 基于突变igg六聚体的治疗性抗体
EP3642230A1 (en) * 2017-06-23 2020-04-29 InflaRx GmbH Treatment of inflammatory diseases with inhibitors of c5a activity
AU2018359237A1 (en) 2017-10-31 2020-04-30 Chemocentryx, Inc. C5aR inhibitor reduction of urinary sCD163
JP7774283B2 (ja) 2017-12-19 2025-11-21 ザ ロックフェラー ユニバーシティー エフェクター機能を改良したヒトＩｇＧのＦｃ領域改変体
US20210070860A1 (en) 2018-03-21 2021-03-11 Dana-Farber Cancer Institute, Inc. Fc variant compositions and methods of use thereof
US20200376135A1 (en) 2018-10-23 2020-12-03 Magenta Therapeutics, Inc. Fc silenced antibody drug conjugates (adcs) and uses thereof
EP3887397A1 (en) 2018-11-28 2021-10-06 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
MA55285A (fr) 2019-03-14 2022-01-19 Morphosys Ag Anticorps ciblant c5ar
US20220306735A1 (en) 2019-08-30 2022-09-29 University Of Kansas Compositions including igg fc mutations and uses thereof
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
WO2021180063A1 (en) 2020-03-09 2021-09-16 I-Mab Biopharma Co., Ltd. Methods for detecting and quantifying biological modifications in antibodies
EP4126222A1 (en) 2020-03-27 2023-02-08 InflaRx GmbH Inhibitors of c5a for the treatment of corona virus infection
AU2022207985A1 (en) * 2021-01-13 2023-07-06 Visterra, Inc. Humanized complement 5a receptor 1 antibodies and methods of use thereof
CA3236564A1 (en) 2021-11-02 2023-05-11 Visterra, Inc. Fc variants with abolished binding to fcgammar and c1q

Also Published As

Publication number Publication date
IL294661A (en) 2022-09-01
KR20220160542A (ko) 2022-12-06
JP2023510844A (ja) 2023-03-15
WO2021146320A9 (en) 2021-11-18
EP4090680A1 (en) 2022-11-23
WO2021146320A8 (en) 2022-07-28
CN115443290A (zh) 2022-12-06
WO2021146320A1 (en) 2021-07-22
US20240076398A1 (en) 2024-03-07
AU2021207627A1 (en) 2022-08-04
TWI869528B (zh) 2025-01-11
CA3166505A1 (en) 2021-07-22
US12415865B2 (en) 2025-09-16
BR112022013780A2 (pt) 2022-10-11
US12187807B2 (en) 2025-01-07
TW202140553A (zh) 2021-11-01
US20220089764A1 (en) 2022-03-24
ZA202208280B (en) 2025-12-17
US11773179B2 (en) 2023-10-03
US20240150488A1 (en) 2024-05-09

Similar Documents

Publication Publication Date Title
WO2019232244A3 (en) Antibody molecules to cd73 and uses thereof
PH12019502875A1 (en) Antibody molecules to cd73 and uses thereof
ZA202208280B (en) Antibody molecules to c5ar1 and uses thereof
PH12020550141A1 (en) Antibody molecules to cd138 and uses thereof
ZA201803366B (en) Antibody molecules to april and uses thereof
WO2017181098A3 (en) Antibody molecules to zika virus and uses thereof
PH12018501206A1 (en) Antibody molecules to pd-1 and uses thereof
JOP20150048B1 (ar) جزيئات جسم مضاد لـ lag-3 واستخداماتها
PH12021553109A1 (en) Humanized antibody molecules to cd138 and uses thereof
WO2019178269A3 (en) Antibodies that bind cd39 and uses thereof
EA202091540A1 (ru) Антитела к lilrb2
WO2022046922A3 (en) Antibody molecules that bind to nkp30 and uses thereof
WO2017019894A8 (en) Combination therapies comprising antibody molecules to lag-3
EA201890315A1 (ru) Молекулы антител, связывающие cd22
MX2018000147A (es) Moleculas de anticuerpo que se unen al grupo de diferenciacion 45 (cd45).
EA202192796A1 (ru) Tigit и pd-1/tigit-связывающие молекулы
MX2019015738A (es) Regimen de dosificacion para anticuerpos anti-tim-3 y usos de los mismos.
ZA202206993B (en) Anti-lilrb1 antibody and uses thereof
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
PH12023550198A1 (en) Antibody molecules to april and uses thereof
PH12021552414A1 (en) Anti fgf23 antibody
MX2019007356A (es) Polipeptidos de union y metodos para fabricarlos.
PH12020552202A1 (en) Antibody molecules to complement component 5 and uses thereof
WO2024168061A3 (en) Antibody molecules binding to sars-cov-2
EA202090891A1 (ru) Молекулы антител против cd138 и их применение